SBT6290, A SYSTEMICALLY ADMINISTERED NECTIN-4-DIRECTED TLR8 IMMUNOBODY (TM) THERAPEUTIC, IS A POTENT HUMAN NECTIN-4 CELL AGONIST FOR THE TREATMENT OF NECTIN-4-EXPRESSING TUMORS

Heather Metz*, Ty Brender, Brenda Stevens, Damien Winship, Jamie Breuk, Michael Corneau, Monica Childs, Jenny Chang, Li-Qun Fan, Hengyu Xu, Jonathan Grey, Jeffrey Adamo, Ben Setter, Ray Carrillo, Sean Smith, Phil Tan, Robert DuRose, Yvette Latchman, Peter Baum, Valerie Odegard. Silverback Therapeutics, Seattle, WA, USA

Background SBT6290 is a novel therapeutic comprised of a selective TLR8 agonist conjugated to a Nectin-4-specific monoclonal antibody, designed for systemic delivery and tumor-localized activation of myeloid cells. Nectin-4 is a cell surface adhesion molecule that is overexpressed in multiple solid tumor types including triple negative breast, head and neck, lung, and uterine cancers, with limited expression in normal tissues. Many solid tumors, including those expressing Nectin-4, are resistant to immunotherapy due to immune-suppressive mechanisms, loss of HLA, low neoantigen availability, and/or minimal T cell infiltrates. These tumors, however, are often replete with myeloid cells. Activation of these cells has emerged as a promising approach in overcoming resistance mechanisms to current cancer immunotherapies. TLR8 is highly expressed in myeloid cell types prevalent in human tumors, including conventional DCs and macrophages. Agonism of TLR8 in human myeloid cells activates a broad spectrum of anti-tumor immune mechanisms, including proinflammatory cytokine production, repolarization of suppressive myeloid cells, and the priming of CTL responses. Here, we show that SBT6290 potently activates human myeloid cells in a Nectin-4-dependent manner and that a mouse surrogate confers single agent anti-tumor activity in preclinical studies. These data support the development of SBT6290 for the treatment of patients with Nectin-4-expressing tumors.

Methods SBT6290 activity was characterized in vitro using coculture systems consisting of human immune cells and Nectin-4-expressing tumor cells. The in vivo efficacy of the SBT6290 surrogate was evaluated as a single agent in mouse tumor models expressing Nectin-4.

Results Studies with human immune cells show that SBT6290 potently induces multiple anti-tumor immune mechanisms, including proinflammatory cytokine and chemokine production, repolarization of suppressive myeloid cells, and the priming of CTL responses. Here, we show that SBT6290 potently activates human myeloid cells in a Nectin-4-dependent manner and that a mouse surrogate confers single agent anti-tumor activity in preclinical studies. These data support the development of SBT6290 for the treatment of patients with Nectin-4-expressing tumors.

Conclusions The preclinical data described here show the potential for SBT6290 to drive robust, single agent anti-tumor responses and support the clinical development of SBT6290 for patients with Nectin-4-expressing tumors.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0712

ANTIBODY-BASED APPROACH OF MT1-MMP METALLOPROTEASE INHIBITION RESULTS IN DECREASED INVASIVE PROPERTIES OF Pancreatic CANCER CELLS

1Nikita Mitkin*, 2Alisa Gorbacheva, 3Alina Ustiugova, 4Aksinya Uvarova, 5Kirill Korneev, 2Vsevolod Pavshintsev, 1Nikita Mitkin. Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Moscow, Russian Federation; 2ADH-Pharm LLC, Moscow, Russian Federation

Background Pancreatic cancer (PC) is one of the most aggressive types of malignant tumors due to the fact, that early stages of the disease are asymptomatic and difficult to diagnose. Matrix metalloproteinases (MMP) play a key role in progression of early PC stages through proteolysis of collagen and a range of regulators that promotes tumor invasion and angiogenesis. MMPs are considered as promising therapeutic targets, but MMP inhibitors exhibit significant efficacy exclusively in a narrow time window, that makes it difficult to use them for prevention of local relapses. That is why MMP inhibitors and blocking antibodies demonstrated moderate results in clinical trials – progressive tumor stages could not be effectively treated with these agents, while their use in the early stages still looks very promising. The aim of the present work was to study the effects of longterm and preventive suppression of the activity of MT1MMP (a key initiator of tumor proliferation and invasion) in pancreatic cancer using the approach of active immunization.

Methods We performed active immunization of SPF C57BL/6 mice using different variants of the vaccine: peptide fragments of MT1-MMP protein or DNA expression vectors coding these peptide fragments. 2-fold vaccine administration and sera collection were performed according to the previously published protocol.1 The sera were collected on the 21 day of the experiment. We applied ELISA to estimate the levels of anti-MT1-MMP antibodies. The functional activity of the sera was tested using enzymatic assay and in vitro metastatic assay according to previously described protocols.2

Results We selected the serum containing high titers of anti-MT1-MMP antibodies which effectively suppressed MT1-MMP activity in the absence of the effect on MMP9. This feature of the serum is fundamental due to the fact, that MMP9 is currently regarded as an undesirable target of anticancer therapy. The functional activity of selected serum and its ability to inhibit pancreatic cancer cell invasion was shown in an in vitro metastatic assay using the PC mouse cell line. In addition, we demonstrated the ability of this serum to inhibit the activity of MMP2 and TGFβ in conditioned mediums and lysates of PC cells, that suggests its additional antitumor properties associated with the suppression of the ability of MT1-MMP to proteolytic activation of a number of tumor modulators.

Conclusions The selected mode could be used for effective immunotherapy against MT1-MMP.

Acknowledgements This project is supported by grant 19-74-00096 from Russian Science Foundation.

References